1. #1
    Super Moderator Nelson Vergel's Avatar
    Join Date
    Sep 2013
    Location
    Houston, Texas, United States
    Posts
    8,080

    Rekynda (bremelanotide) for Female Sexual Disorder

    Rekynda (bremelanotide), an investigational product, is thought to possess a novel mechanism of action, activating endogenous melanocortin pathways involved in sexual desire and response.

    The two Phase 3 studies for HSDD in pre-menopausal women consisted of double-blind placebo-controlled, randomized parallel group studies comparing a subcutaneous dose of 1.75 mg Rekynda delivered via an auto-injector pen to placebo. Each trial consisted of more than 600 patients randomized in a 1:1 ratio to either the treatment arm or placebo with a 24 week evaluation period. In both clinical trials, Rekynda met the pre-specified co-primary efficacy endpoints of improvement in desire and decrease in distress associated with low sexual desire as measured using validated patient-reported outcome instruments.

    http://finance.yahoo.com/news/amag-p...130000216.html


    Founder
    www.ExcelMale.com
    www.DiscountedLabs.com
    www.ClinicOptimizers.com
    www.TRTData.com
    www.MyHealthGraphs.com

    Author of Testosterone: A Man's Guide & Built to Survive

    Please no private messages. I answer questions on the forum for all to benefit.

  2. # ADS
    Purchase From Our Affiliates
    Join Date
    Always
    Location
    Houston, TX
    Posts
    51
    Help Excelmale

    Defy
     

  3. #2
    May offer some promise as an adjunct for post-menopausal women (wouldn't offer some of the health benefits of appropriately administered BHRT) or as standalone treatment for premenopausal females with HSDD not needing BHRT. They are developing it as an "as needed" libido/arousal/function booster similar to "as needed" viagra.

    This compound is the same as the peptide PT-141 (still available through some of the research peptide sites) and was isolated from melanotan (another research peptide).

    BTW, the stock is $0.50 if anyone is a gambler...but do NOT take stock advice from me!
    Lead Physician & Medical Director
    www.defymedical.com

    NOTE: Comments on this forum are NOT medical advice and are no substitute for individualized patient care. Comments on this forum do not constitute or establish a physician-patient relationship. Please consult your personal physician prior to initiating or changing ANY treatment regimen.

  4. #3
    Super Moderator Nelson Vergel's Avatar
    Join Date
    Sep 2013
    Location
    Houston, Texas, United States
    Posts
    8,080
    Palatin Technologies announced that its exclusive North American licensee for bremelanotide, AMAG Pharmaceuticals, has submitted a New Drug Application (NDA) to the FDA for Rekynda (bremelanotide) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. If approved, bremelanotide would become the first and only as desired pharmacologic option in the U.S. indicated for the treatment of HSDD in premenopausal women. Palatin expects that within 60 days the FDA will determine whether the NDA is complete for filing.

    Palatin previously announced positive results for two Phase III trials of bremelanotide for the treatment of HSDD in premenopausal women that met the pre-specified co-primary efficacy endpoints. The Phase III RECONNECT studies for HSDD in premenopausal women consisted of two double-blind placebo-controlled, randomized parallel group studies comparing the as desired use of 1.75 mg of bremelanotide versus placebo, in each case, delivered via a subcutaneous auto-injector. Each trial consisted of more than 600 patients randomized in a 1:1 ratio to either the treatment arm or placebo with a 24 week evaluation period. In both clinical trials, bremelanotide met the pre-specified co-primary efficacy endpoints of median improvement in desire and decrease in distress associated with low sexual desire as measured using validated patient-reported outcome instruments. Women in the trials had the option, after completion of the trial, to continue in an open-label safety extension study for an additional 52 weeks. Nearly 80% of patients who completed the randomized portion of the study elected to remain in the open-label portion of the study. In the Phase III clinical trials, the most frequent adverse events were nausea, flushing, and headache, which were generally mild-to-moderate in intensity and were transient. Source


    More details on the drug

Thread Information

Users Browsing this Thread

There are currently 1 users browsing this thread. (0 members and 1 guests)

Similar Threads

  1. Replies: 0
    Last Post: 07-06-2016, 11:07 AM
  2. Replies: 0
    Last Post: 01-20-2016, 11:31 AM
  3. FDA approves first treatment for sexual desire disorder
    By Nelson Vergel in forum HRT in Women
    Replies: 8
    Last Post: 08-20-2015, 03:03 PM
  4. Do you have penile dysmorphic disorder (PDD)?
    By Nelson Vergel in forum Health & Wellness
    Replies: 0
    Last Post: 03-05-2015, 01:10 PM
  5. How to Know if You Have a Testicular Disorder
    By Nelson Vergel in forum Testosterone- Miscellaneous Studies
    Replies: 1
    Last Post: 01-02-2014, 07:12 PM

Tags for this Thread

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •